People · Operator
Named in public records as an officer, director or promoter · active 2010–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intarcia Therapeutics, Inc | — | Biotechnology | Growth/Late | $1.2B | $8.4B | 2010 |
| Pulmatrix Inc | — | Biotechnology | Series B | $69.6M | $396.9M | 2015 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.1M | 2015 |
| i2O Therapeutics, Inc. | — | Biotechnology | Series B | $43.9M | $34.9M | 2021 |
| SpringLeaf Therapeutics, Inc. | — | Pharmaceuticals | Series B | $34.1M | $647.7M | 2011 |
Kurt Graves at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kurt Graves on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 2 | 23 |
| Michael Higgins | 2 | 9 |
| Terrance McGuire | 2 | 9 |
| SCOTT ROCKLAGE | 2 | 9 |
| Robert Clarke | 2 | 7 |
| David Hava | 2 | 2 |
| David Maki | 2 | 2 |
| Michael Williams | 1 | 27 |
| Bryan Roberts | 1 | 18 |
| Michael Greeley | 1 | 15 |
| Ed Mathers | 1 | 11 |
| Brian Gallagher | 1 | 11 |
| Jeffrey McCarthy | 1 | 7 |
| PATRICK CONWAY | 1 | 6 |
| Amit Munshi | 1 | 5 |
| Gino Santini | 1 | 5 |
| Glen Sato | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| MICHAEL J. HIGGINS | 1 | 4 |
| Michael Cima | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.